<DOC>
	<DOC>NCT00468975</DOC>
	<brief_summary>A study to determine the ability of different doses of PF-610,355 to open the airways in asthmatic patients by comparison with placebo and a marketed drug that also opens the airways in asthmatic patients.</brief_summary>
	<brief_title>A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients.</brief_title>
	<detailed_description />
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Reversible asthmatic patients (&gt;15% increase in FEV1 following 200ug salbutamol). FEV1 greater than or equal to 60% predicted Stable disease for at least the previous 3 months Subjects requiring rescue medication on greater than 2 occasions in the 72 hours prior to screening Subjects with a history of pulmonary disease other than asthma.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>